Compare · CTNM vs LLY
CTNM vs LLY
Side-by-side comparison of Contineum Therapeutics Inc. (CTNM) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTNM and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 1753.8x CTNM ($622.6M).
- Over the past year, CTNM is up 48.0% and LLY is up 57.8% - LLY leads by 9.8 points.
- LLY has been more active in the news (16 items in the past 4 weeks vs 2 for CTNM).
- LLY has more recent analyst coverage (25 ratings vs 5 for CTNM).
- Company
- Contineum Therapeutics Inc.
- Eli Lilly and Company
- Price
- $16.56+1.97%
- $1159.75+0.10%
- Market cap
- $622.6M
- $1.09T
- 1M return
- +4.02%
- +3.44%
- 1Y return
- +47.99%
- +57.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 2
- 16
- Recent ratings
- 5
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CTNM
- Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.
- CEO and President Stengone Carmine N. sold $40,029 worth of shares (2,500 units at $16.01) as part of a pre-agreed trading plan and exercised 2,500 shares at a strike of $1.01 (SEC Form 4)
- SEC Form 10-Q filed by Contineum Therapeutics Inc.
- Contineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
- Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.
- Contineum Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Scientific Officer Lorrain Daniel S. exercised 1,040 shares at a strike of $1.01 and sold $16,640 worth of shares (1,040 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)
- CEO and President Stengone Carmine N. exercised 2,500 shares at a strike of $1.01 and sold $40,000 worth of shares (2,500 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)
Latest LLY
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)